Novilora for Chemo Nerve Pain: What the Evidence Actually Shows

The chemo is finished. The scans look good. But your hands still tingle when you try to button a shirt, and your feet burn at night when you are trying to sleep.Then you see it — an ad, a headline, or a post in a support group. A supplement called Novilora just launched in the United States, made specifically for nerve damage from chemotherapy. It has a study behind it. It was developed by an oncologist. It sounds, finally, like someone built something for the problem nobody seems able to fix.

That hope makes complete sense. Chemo nerve pain — doctors call it chemotherapy-induced peripheral neuropathy, or CIPN — is one of the most common and most stubborn side effects of cancer treatment. And the honest truth is that medicine has very little to offer for it.So what is Novilora, what does its one study actually show, and what can that study not tell us? This post walks through the evidence the same way we checked apple cider vinegar and cancer — claim by claim, with the numbers on the table.

First, the problem: nerve damage that outlasts chemo

Some chemotherapy drugs are hard on nerves, especially the long nerves that run to your hands and feet. Paclitaxel, oxaliplatin, vincristine, and the platinum drugs are the usual suspects. The damage shows up as numbness, tingling, burning, shooting pain, weakness, and trouble with balance.

Here is how common it is. A large review of 31 studies covering more than 4,100 patients found:

  • About 68% of patients have CIPN in the first month after chemotherapy- About 60% still have it around three months out
  • About 30% still have it six months or longer after treatment ends

Read those numbers again, because they matter twice in this story. First, they show how many people are living with this. Second — and keep this in your pocket for later — they show that for many people, CIPN slowly gets better on its own once chemo stops. Roughly speaking, the share of patients with symptoms falls by more than half between month one and month six, with no treatment at all.

That natural recovery is normal and welcome. It is also the single biggest reason a study without a comparison group is so hard to interpret. We will come back to that.

CIPN affects about 68% of patients in the first month after chemo — and for many, it slowly improves on its own. Any study of a CIPN product has to be read with that in mind.

If you want the bigger picture of how nerve damage unfolds over time, our post on the four paths chemo nerve damage can take follows patients for years after treatment, not just months.

What Novilora is — and what it is not

Novilora opened for presale in the United States on November 17, 2026, with the first shipments expected in January 2027. It is not a brand-new invention. It is the American name for a supplement sold in Europe as OnLife, developed and produced in Italy by a company called Again Life Italia, and brought to the US with an American partner, CaraKit.

The formula was created by Dr. Raffaele Migliaccio, an Italian internist and oncologist who has spent his career in supportive cancer care — the branch of medicine focused on quality of life during and after treatment. He holds the patent on the combination.

What is inside it?

Novilora is not a single-ingredient product. Each tablet combines:

  • Palmitoylethanolamide (PEA) — a fatty compound your own body makes, studied for its role in calming irritated nerves and inflammation signals
  • A defined mix of fatty acids — including EPA and DHA (the omega-3s in fish oil), alpha-linolenic acid, linoleic acid, oleic acid, palmitic acid, and stearic acid

The thinking behind the formula is straightforward. Nerves are wrapped in fatty insulation called myelin, and nerve cell membranes are built largely from fats. The formula aims to supply building blocks for nerve structure while PEA works on the signaling side. In the study we are about to look at, patients took two tablets a day for three months.

To its credit, the company's own website says plainly that a scientific rationale "does not establish clinical efficacy." That is exactly right, and it is the right standard to hold every product to — including this one.

What it is not

Novilora is not an FDA-approved drug. It is a dietary supplement, which means the FDA did not review it for safety or effectiveness before it went on sale, the way it would a prescription medicine. The company's launch release carries the standard supplement disclaimer: the product "is not intended to diagnose, treat, cure or prevent any disease."

That is not a reason to dismiss it. It is a reason to read its study carefully — so let us do that.

The STEFANO study: the one piece of clinical evidence

Everything Novilora can claim rests on a single study, called STEFANO, published in 2021 in the journal Oncology Research and Treatment. Here is what the researchers did.

They enrolled patients at 21 oncology practices in Germany who had established CIPN — nerve damage that was already present after chemotherapy ended. One group had breast cancer and had received paclitaxel. The other had colon cancer and had received oxaliplatin-based treatment. Everyone took the supplement (under its European name, OnLife) for three months, starting after chemo was over. Doctors graded each patient's sensory neuropathy (feeling: numbness, tingling, pain) and motor neuropathy (movement: weakness, function) at the start and at the end.

In total, 146 patients were analyzed: 75 in the breast cancer group and 71 in the colon cancer group. About 84% finished the full three months.

Now the findings, one at a time.

Finding 1: In the paclitaxel group, about 1 in 3 patients improved by doctor grading

Among the breast cancer patients, doctors rated sensory neuropathy as improved in 31.1% and unchanged (stabilized) in 54.1%. Motor neuropathy improved in 37.5% and stabilized in 50.0%.

Add improved and stabilized together and you get the number the company highlights: about 85% of paclitaxel patients were rated as improved or stable on sensory symptoms, and about 87.5% on motor symptoms.

Finding 2: The oxaliplatin group improved less

Among the colon cancer patients, sensory neuropathy improved in 16.9% and stabilized in 56.3%. Motor neuropathy improved in 20.0% and stabilized in 50.0%. Real movement, but roughly half the improvement rate of the paclitaxel group — one reason the researchers say the signal looks strongest after paclitaxel.

Finding 3: Patients' own reports pointed the same direction

The study also asked patients directly, using a standard questionnaire (the EORTC QLQ-CIPN20). Among paclitaxel patients, 45.9% reported fewer sensory symptoms and 37.5% reported fewer motor symptoms. Among oxaliplatin patients, the figures were 23.9% and 22.0%.

Quality-of-life scores rose too: overall health status improved by an average of 13.1 points in the breast cancer group and 11.5 points in the colon cancer group, on a 100-point scale.

Finding 4: Most people tolerated it, but not everyone

Twenty-four of the 146 patients stopped early. Nine stopped because of intolerance — stomach and gut upset, a hypersensitivity reaction, or intolerance to the smell or taste. The paper did not publish a full side-effect table, so the complete tolerability picture is not available.

Those are the results, and on their face they sound encouraging. Now for the part of the story that decides how much weight they can carry.

The catch: there was no comparison group

STEFANO was a single-arm study. That means every patient got the supplement, and there was no placebo group and no group that got nothing. Nobody was randomly assigned. The researchers simply watched what happened over three months and reported it.

Why does that matter so much here? Go back to those prevalence numbers from the beginning of this post. CIPN fades on its own for many people once chemo ends — the share of patients with symptoms drops from about 68% at one month to about 30% at six months or later, all by itself. STEFANO started the supplement right after chemo ended and measured three months later — exactly the window when natural recovery is doing its heaviest work.

So when 31% of paclitaxel patients improved, the honest question is: how many would have improved anyway, tablet or no tablet? This study cannot answer that question. It was not built to. The researchers say so themselves, in almost those words: without a control group, the effect of the supplement cannot be separated from recovery that happens after chemotherapy stops.

A few more limits worth knowing:

  • The analysis was exploratory. The study ran no statistical tests designed to prove the supplement worked; it described what it saw.
  • A lot of patient-reported data was missing. In the colon cancer group, roughly 44% to 48% of the patient questionnaire data could not be evaluated.
  • The study was funded by a company (Swiss Medical Food AG) connected to the product — common in supplement research, and one more reason independent confirmation matters.
  • The authors' own conclusion was that the findings are promising and that a randomized, multicenter trial is warranted — the larger, placebo-controlled kind of study that can actually settle the question. That trial has not been published yet.

None of this makes STEFANO worthless. A peer-reviewed study of 146 real patients, with doctor grading and patient reports moving in the same direction, is a genuine signal — more evidence than most supplements ever produce. But a signal is a starting point, not a verdict. Think of it like a promising weather forecast from a single station: worth paying attention to, not worth betting the house on.

A single-arm study can show that people improved while taking a product. Only a comparison group can show they improved because of it.

What the guidelines say

The American Society of Clinical Oncology (ASCO) maintains the reference guideline on CIPN, updated in 2020. Its position is clear:

  • No supplement, vitamin, or drug is recommended to prevent CIPN. Not one — the evidence is not there for any of them.
  • For established, painful CIPN, exactly one medicine has enough evidence to recommend: duloxetine, a prescription drug — and even its benefit is described as modest.

Novilora does not change that guideline picture today, because a single-arm observational study is not the kind of evidence guidelines are built on. If a randomized trial confirms the STEFANO signal, that conversation can change. Until then, Novilora sits in the large category of "plausible, unproven" — alongside things like the ear seeds for chemo nerve pain we covered in a recent trial report, where early results were interesting and the researchers likewise called for bigger, better-controlled studies.

Three myths to watch for as the marketing spreads

A US launch means ads, testimonials, and social posts are coming. The company's site already features a powerful personal story — one survivor whose foot pain dropped, in her account, from a 10 to a 2. Stories like that are real experiences, and they are also the weakest form of evidence. Here is how to keep your footing:

Myth 1: "It's used in Europe, so it's proven." European use means the product has been sold and studied there — as a supplement, under supplement rules. The one clinical study is STEFANO, with the limits above. Longevity on a shelf is not the same as proof.

Myth 2: "85% of patients benefited." That headline number combines improved with stayed the same. Staying the same can be valuable — neuropathy that stops getting worse matters — but in a study with no comparison group, some of those patients would have stayed the same or improved with no product at all. The improvement-only numbers (31% and 17% for sensory symptoms) are the more conservative read.

Myth 3: "Natural means it can't hurt, so why not just try it?" Nine people in STEFANO stopped because their bodies objected — gut upset, a hypersensitivity reaction, taste and smell intolerance. Supplements can also interact with medicines and complicate your care team's picture of what is causing what. "Just trying it" without telling your team is the one version of this that is genuinely risky.

If you are considering it: a sensible way to decide

You do not need this post's permission, and you do not need to be talked out of your hope. If you are living with burning feet and clumsy hands, wanting to try something is human. Here is how to approach it with clear eyes:

1. Tell your oncology team first — and ask the pharmacist, too. Oncology nurses who covered this launch made the same point: supplements belong in your medication list, reviewed like anything else you take. Your team can flag interactions and will want to know what you are taking if your symptoms change.

2. Match your situation to the study. STEFANO studied people whose chemo was finished, whose nerve damage came from paclitaxel or oxaliplatin, and who took the product for three months. If you are mid-treatment, or your neuropathy came from a different drug, you are outside what was studied — another reason the conversation with your team matters.

3. Set a personal finish line. If you and your team decide to try it, agree in advance on what "working" would look like (buttoning a shirt more easily? sleeping through the night? walking the block more steadily?) and a point — the study used three months — to honestly judge whether you got there.

4. Keep doing the unglamorous things that protect you now. Neuropathy safety does not wait for any supplement: check your feet daily for cuts you might not feel, test bath water with a thermometer or your elbow, use handrails, clear trip hazards, and wear firm, closed-toe shoes. And report new or worsening symptoms — during treatment, worsening CIPN is a reason your team may adjust doses, which is a proven lever, unlike any supplement.

5. Budget honestly. Novilora is a presale product shipping in January 2027, sold directly by the company. Supplements are rarely covered by insurance. Whatever the checkout price, weigh it as money spent on a possibility, not a proven treatment — and never let it crowd out things with stronger evidence behind them, like physical therapy for balance or a duloxetine conversation if your pain qualifies.

Watch for these — and tell your team promptly

Whether or not you try any supplement, contact your care team if you notice:

  • Numbness spreading, or new weakness — trouble rising from a chair, climbing stairs, or gripping objects
  • A fall, a near-fall, or new unsteadiness when walking
  • Burns, cuts, or sores on your feet or hands that you did not feel happen
  • Pain that breaks through your sleep most nights
  • New stomach upset, rash, or swelling after starting any new supplement — possible intolerance or allergy
  • Symptoms appearing while you are still on treatment — early reporting gives your team the chance to adjust the chemo dose itself

Questions to ask your oncology team

  1. My neuropathy came from my specific chemo drug — was it one of the drugs in the Novilora study (paclitaxel or oxaliplatin)?
  2. Given my other medicines, is there any interaction or safety concern with a PEA and fatty-acid supplement?
  3. Would you add it to my medication list so the whole team can see it?
  4. My pain is significant — do I qualify for the one treatment ASCO does recommend, duloxetine?
  5. How are we grading my neuropathy at each visit, and can we also track how it feels to me, since doctor grades can underestimate it?
  6. If I try it, what change should I realistically look for, and over what time frame?
  7. At what point would we say it is not helping and stop?
  8. Are there clinical trials for CIPN I could join — including any randomized trial of this or similar products?
  9. Would physical or occupational therapy help my balance and hand function in the meantime?
  10. What should I be doing at home to protect my hands and feet while the nerves recover?

The bottom line

Watch for these: talk to your team promptly if you notice

  • Mouth or throat burning, or mouth sores getting worse after acidic drinks
  • Nausea, fullness, bloating, or reflux that is getting worse rather than better
  • Eating or drinking noticeably less since starting any new remedy or supplement
  • Tooth sensitivity or visible enamel changes
  • Diarrhea or stomach cramps after raw or unpasteurized products, especially with fever
  • A skin burn or a lesion that is changing, growing, or not healing
  • Any urge to skip or postpone a treatment session to try a remedy first. Say this one out loud to your team; they would rather know

Questions to ask your oncology team

  1. I keep getting sent videos about apple cider vinegar. Is there any evidence it helps with my cancer?
  2. Is it safe for me to use it in food during my treatment?
  3. I have mouth sores. Are there drinks or home remedies I should specifically avoid?
  4. My stomach already feels slow and full quickly. Could anything I am taking be making that worse?
  5. Does vinegar interact with any of my medicines, including insulin or water pills?
  6. Are raw or unpasteurized products risky for me while my blood counts are low?
  7. What should I do to protect my teeth during treatment?
  8. If I want to try complementary approaches, which ones have actual evidence for my symptoms?
  9. How do I tell whether a health claim I see online is trustworthy?
  10. Who should I ask before starting any supplement, gummy, or home remedy?
  • Novilora (Europe's OnLife) launched for US presale on November 17, 2026; first shipments are expected in January 2027. It is a supplement, not an FDA-approved drug.
  • Its formula — PEA plus a defined fatty-acid mix — was designed by an Italian oncologist around nerve structure and signaling.
  • The one clinical study, STEFANO (146 patients), found doctor-graded sensory improvement in 31.1% of paclitaxel patients and 16.9% of oxaliplatin patients after three months, with most others stable, and patient reports moving the same way.
  • But STEFANO had no comparison group, and CIPN often improves on its own after chemo — so the study cannot show how much of the improvement the supplement caused. Its own authors call for a randomized trial.
  • ASCO's guideline still recommends no supplement for CIPN and names duloxetine as the only supported option for established painful CIPN.
  • If you try it: tell your team, match your case to the study's, set a three-month finish line, and keep up the safety habits that protect you today.

The fairest one-line summary: Novilora is a thoughtfully built supplement with a genuinely interesting early signal — and the study that would prove it works has not been done yet. Wanting better options for chemo nerve pain is exactly right. Holding new products to the standard of proof is how those better options eventually arrive.

Frequently asked questions

What is Novilora?

Novilora is a dietary supplement that launched for US presale on November 17, 2026. It is the American name for OnLife, a supplement sold in Europe, made in Italy by Again Life Italia. It combines palmitoylethanolamide (PEA) with a defined mix of fatty acids, and it is marketed for nerve health in people with chemotherapy-induced peripheral neuropathy (CIPN).

Is Novilora FDA approved?

No. Novilora is a dietary supplement, not an FDA-approved drug. Supplements do not go through FDA review for safety and effectiveness before sale the way prescription medicines do, and the company states the product is not intended to diagnose, treat, cure, or prevent any disease.

What did the STEFANO study find?

STEFANO followed 146 patients in Germany with established CIPN after paclitaxel (breast cancer) or oxaliplatin-based therapy (colon cancer) who took the supplement for three months after chemo ended. Doctors rated sensory neuropathy improved in 31.1% of paclitaxel patients and 16.9% of oxaliplatin patients, with most of the rest stable. Patients' own symptom reports improved in the same direction, and quality-of-life scores rose.

Why can't the study prove Novilora works?

Because everyone in the study took the supplement and there was no comparison group taking a placebo or nothing. CIPN frequently improves on its own in the months after chemotherapy ends, so the study cannot separate the supplement's effect from natural recovery. The study's authors say a randomized, placebo-controlled trial is needed.

What does ASCO recommend for chemo nerve pain?

The ASCO guideline recommends no agent — supplement or drug — to prevent CIPN. For established painful CIPN, duloxetine is the only treatment with enough supporting evidence to recommend, and its benefit is modest. Talk with your oncology team about whether it fits your situation.

When can people in the US get Novilora, and how is it taken?

The company opened a presale on November 17, 2026, with the first US shipments expected in January 2027. In the STEFANO study, patients took two tablets daily for three months, starting after chemotherapy ended. Follow your own care team's guidance over any general description.

Is Novilora safe?

In STEFANO, most patients completed three months, but 24 of 146 stopped early and 9 stopped for intolerance, including gastrointestinal upset, a hypersensitivity reaction, and smell or taste intolerance. The study did not publish a full side-effect table. Supplements can also interact with other medicines, so tell your oncology team and pharmacist before starting.

Should I take Novilora during chemotherapy?

STEFANO only studied people who started the supplement after chemotherapy ended. There is no published evidence here about taking it during active treatment. That is a decision to make with your oncology team, not from an advertisement — some supplements are discouraged during treatment itself.

Sources

Next
Next

Apple Cider Vinegar and Cancer: What the Evidence Actually Says